It has been found that the compound, LDN-0060609, significantly inhibits PERK-mediated phosphorylation of eIF2α in rat astrocytes, which suggests that it may be a suitable drug for the treatment of neurological diseases (35). Here, EIF2A is linked to nervous system disorder.